Long-Term Outcomes in SLE at Peking University People's Hospital

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial at Peking University People's Hospital is studying long-term outcomes for patients with Systemic Lupus Erythematosus (SLE), a condition that affects the immune system. Researchers want to learn more about how the disease affects patients over time, including how active the disease is, which organs it may involve, overall survival rates, and the quality of life for patients. This information will help doctors provide better, personalized care for patients with SLE, especially within the Chinese population.

To participate in this study, you need to be at least 18 years old and diagnosed with SLE based on specific classification criteria. If you join, you will be followed over time to track your health and how the disease progresses. The study is currently looking for participants, and it aims to gather valuable insights that can improve future treatments and management of SLE.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * All patients must meet at least one of the following classification criteria for Systemic Lupus Erythematosus (SLE):
• • The 1997 American College of Rheumatology (ACR) Revised Classification Criteria; The 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria; The 2019 EULAR/ACR Classification Criteria for SLE. All patients must be over the age of 18 and competent to provide written consent.
• Exclusion Criteria:
• • Patients less than 18 years of age and patients who are unable to consent are excluded from the study.